Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
ASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer
To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug giredestrant even as competition mounts. | To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug giredestrant. Instead, the Swiss pharma has been inspired to open a new phase 3 study in the adjuvant setting.
1,307 words~6 min read
